CopyPastehas never been so tasty!

Cancer Monoclonal Antibodies Market to 2015

by anonymous

  • 0
  • 0
  • 0

Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In order to treat the life-threatening disease more efficiently and with enhanced specificity, monoclonal antibodies have become the most widely used cancer therapy. As per the findings of our new research report, cancer monoclonal antibodies provide high specificity to treat tumors and several formats exist for the types of cancer monoclonal antibodies available.

According to “Cancer Monoclonal Antibodies Market to 2015”, cancer monoclonal antibodies have evolved greatly from the first time they were implemented, and have created a strong demand since then. In the recent time, some very important monoclonal antibodies, such as Yervoy (ipilimumab) have entered the market. Our study expects that these antibodies will consume the share of leading monoclonal antibody products in the coming years.

Our research observed that the strong demand for effective cancer treatments and high prevalence are driving the cancer monoclonal antibodies market which is anticipated to grow at a CAGR of around 7% during 2012-2015. While research and innovation in this field have been growing exorbitantly, the industry has witnessed a large number of consolidation activities. In the report, we have also studied how technological advancements and a subsequent increase in number of approvals are influencing the market growth.

During the study of latest industry trends and drivers, we observed that conjugated cancer antibody therapies offer efficient cancer treatments. Besides, bispecific antibodies (BiAbs) present a unique opportunity to redirect immune effector cells to kill cancer cells. Our report covers the analysis of the entire monoclonal antibody market for cancer, and presents market forecasts for leading products. The geographic analyses for key markets, carried out in the research, foresee that the US and Europe will continue holding significant market shares, and Japan will exhibit unaltered double digit growth.

In our research report, we have conducted a comprehensive pipeline analysis of the expected cancer monoclonal antibodies and their phase of development. We found that maximum products are expected in the field of breast cancer in near future. The study discusses in detail the key market players, their business activities, key monoclonal antibody products which are available in the market and in pipeline. Overall, we expect the cancer monoclonal antibody market to show stupendous growth and great evolution in the coming years.

1. Analyst View
2. Research Methodology
3. The Global Burden of Cancer
3.1 Cancer - A Leading Cause of Death
3.2 Current and Future Cancer Cases: By Type and Geography
3.3 Common Causes of Cancer
4. Global Cancer Market Outlook to 2015
4.1 Current and Future Growth
4.2 Analysis by Therapeutic Areas
5. Monoclonal Antibodies: Introduction and Working
5.1 Types of Mabs
5.1.1 Murine Antibodies
5.1.2 Chimeric and Humanized Antibodies
5.1.3 Fully Human Antibodies
5.2 Conjugated Cancer Therapies using MAbs
5.2.1 Radioimmunotherapy
5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)
5.2.3 Immunoliposomes
5.2.4 Immunotoxin
5.2.5 Immunocytokine
5.3 mAb Therapies
5.3.1 Avastin/Bevacizumab
5.3.2 Rituxan/Rituximab
5.3.3 Herceptin/Trastuzumab
5.3.4 Erbitux/Cetuximab
5.3.5 Vectibix/Panitumumab
5.3.6 Campath/Alemtuzumab
5.3.7 Zevalin/ Ibritumomab
5.3.8 Bexxar/Tositumomab
5.3.9 Arzerra/Ofatumumab
6. Industry Trends and Drivers
6.1 Strategic Activity Building Up in the Market
6.2 New Approvals Showing Promising Future
6.3 Bispecific Antibodies: Emerging Therapeutic Treatment
6.4 Japan Gearing-up for Cancer Antibodies
7. Global Anti-Neoplastic mAbs Market Outlook to 2015
7.1 Market Size
7.2 Anti-Neoplastic mAbs: Approval History and Market Share
7.3 Anti-Neoplastic mAbs: Current and Future Market Size
7.3.1 Avastin (Bevacizumab)
7.3.2 MabThera/Rituxan (Rituximab)
7.3.3 Herceptin (Trastuzumab)
7.3.4 Erbitux (Cetuximab)
7.3.5 Vectibix (Panitumumab)
7.4 Country-Level Analysis
7.4.1 US
7.4.2 Japan
7.4.3 Europe
7.5 Market Share of Key Players
8. Pipeline Analysis for Anti-Neoplastic Monoclonal Antibodies
9. Competitive Landscape
9.1 Roche
9.2 Immunomedics
9.3 Bristol-Myers Squibb
9.4 AstraZeneca
9.5 Eli Lilly
9.6 Amgen

For more information kindly visit :
Cancer Monoclonal Antibodies Market to 2015


Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:!/Sandhya3Bs
Our Blogs:!/bharatbook

Add A Comment: